Roivant Sciences
ROIV • NASDAQ
Roivant Sciences is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Matthew Gline, with a market cap of $19.0B.
CEOMatthew Gline
Next Earnings
Upcoming earnings announcement for Roivant Sciences
Date
Thursday, May 28, 2026 (in 2 months)
Timing
Before Market Open (7:00 AM New York)
Fiscal Period
Q4 2026
EPS Estimate
-$0.34
Revenue Estimate
$3.7M
Earnings History
Past 12 earnings reports for Roivant Sciences
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Feb 6, 2026 | Q3 2026 | -$0.24Est: -$0.34 | +29.4% | $2.0MEst: $6.1M | -67.4% |  10-Q |
| Nov 10, 2025 | Q2 2026 | -$0.28Est: -$0.32 | +12.5% | $1.6MEst: $6.7M | -76.5% | 10-Q |
| Aug 11, 2025 | Q1 2026 | -$0.25Est: -$0.26 | +3.8% | $2.2MEst: $7.2M | -69.8% | 10-Q |
| May 29, 2025 | Q4 2025 | -$0.22Est: -$0.16 | -37.5% | $7.6MEst: $62.2M | -87.8% | 10-K |
| Feb 10, 2025 | Q3 2025 | -$0.20Est: -$0.24 | +16.7% | $9.0MEst: $6.3M | +42.5% | 10-Q |
| Nov 12, 2024 | Q2 2025 | -$0.25Est: -$0.26 | +3.8% | $4.5M | — | 10-Q |
| Aug 8, 2024 | Q1 2025 | -$0.17Est: -$0.26 | +34.6% | $55.1MEst: $31.6M | +74.5% | 10-Q |
| May 30, 2024 | Q4 2024 | -$0.19Est: -$0.30 | +36.7% | $28.9MEst: $32.1M | -9.9% | 10-K |
| Feb 13, 2024 | Q3 2024 | -$0.21Est: -$0.32 | +34.4% | $37.1MEst: $32.8M | +13.3% | 10-Q |
| Nov 13, 2023 | Q2 2024 | -$0.40Est: -$0.31 | -29.0% | $37.1MEst: $30.1M | +23.2% | — |
| Aug 14, 2023 | Q1 2024 | -$0.38Est: -$0.30 | -26.7% | $21.6MEst: $25.1M | -13.7% | 10-Q |
| Jun 28, 2023 | Q4 2023 | -$0.20Est: -$0.36 | +44.4% | $27.4MEst: $21.5M | +27.2% | — |